Eli Lilly的或forglipron在降低2型糖尿病患者的血糖和体重方面表现优于硫酸盐,FDA的决定预计将在Q2 2026年作出。 Eli Lilly's orforglipron outperformed semaglutide in lowering blood sugar and weight in type 2 diabetes patients, with FDA decision expected in Q2 2026.

礼来公司的口服GLP-1药物orforglipron在一项三期临床试验中优于口服司美格鲁肽，A1C降低了2.2%，并在2型糖尿病成人52周内平均减轻了19.7磅——比司美格鲁肽高73.6%。 Eli Lilly’s oral GLP-1 drug orforglipron outperformed oral semaglutide in a Phase 3 trial, reducing A1C by 2.2% and causing an average 19.7 lb weight loss—73.6% greater than semaglutide—over 52 weeks in adults with type 2 diabetes. 这种药物每天服用一次,没有食物限制,也改善了心血管风险因素。 The drug, taken once daily without food restrictions, also improved cardiovascular risk factors. 尽管 orforglipron 的效果更强,但由于胃肠道副作用,患者的停药率更高. Though more effective, orforglipron had higher discontinuation rates due to gastrointestinal side effects. 莉莉已将其提交40多个国家进行监管审查,预计美国将于2026年第二季度作出决定。 Lilly has submitted it for regulatory review in over 40 countries, with a U.S. decision expected in the second quarter of 2026.